BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Overview
USA - NASDAQ:BDRX - US59564R8806 - ADR
BDRX Key Statistics, Chart & Performance
The current stock price of BDRX is 6.75 USD. In the past month the price increased by 19.84%. In the past year, price decreased by -88.03%.
BDRX Latest News, Press Relases and Analysis
BDRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.59 | 403.84B | ||
| AMGN | AMGEN INC | 13.57 | 159.30B | ||
| GILD | GILEAD SCIENCES INC | 15.69 | 150.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.19 | 109.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.92B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 62.03B | ||
| ARGX | ARGENX SE - ADR | 88.32 | 50.08B | ||
| INSM | INSMED INC | N/A | 33.90B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.59B | ||
| NTRA | NATERA INC | N/A | 25.82B | ||
| BIIB | BIOGEN INC | 9.23 | 21.66B |
Related stock screener links
About BDRX
Company Profile
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Company Info
BIODEXA PHARMACEUTICALS-ADR
1 Caspian Point, Caspian Way
Abingdon OXFORDSHIRE GB
Employees: 13
Phone: 4401235888300
BIODEXA PHARMACEUTICALS-ADR / BDRX FAQ
What is the stock price of BIODEXA PHARMACEUTICALS-ADR today?
The current stock price of BDRX is 6.75 USD. The price decreased by -10.6% in the last trading session.
What is the ticker symbol for BIODEXA PHARMACEUTICALS-ADR stock?
The exchange symbol of BIODEXA PHARMACEUTICALS-ADR is BDRX and it is listed on the Nasdaq exchange.
On which exchange is BDRX stock listed?
BDRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIODEXA PHARMACEUTICALS-ADR stock?
7 analysts have analysed BDRX and the average price target is 183.6 USD. This implies a price increase of 2620% is expected in the next year compared to the current price of 6.75. Check the BIODEXA PHARMACEUTICALS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIODEXA PHARMACEUTICALS-ADR worth?
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a market capitalization of 4.18M USD. This makes BDRX a Nano Cap stock.
How many employees does BIODEXA PHARMACEUTICALS-ADR have?
BIODEXA PHARMACEUTICALS-ADR (BDRX) currently has 13 employees.
What are the support and resistance levels for BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a support level at 7.55 and a resistance level at 8.85. Check the full technical report for a detailed analysis of BDRX support and resistance levels.
Should I buy BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BDRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BDRX, evaluating the profitability, health, valuation and growth aspects
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Sales and EPS estimates to see what analysts future expectations are.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Chart to make your own analysis
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Latest news and press-releases to stay up to date.
Does BIODEXA PHARMACEUTICALS-ADR (BDRX) stock pay dividends?
BDRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIODEXA PHARMACEUTICALS-ADR (BDRX)?
BIODEXA PHARMACEUTICALS-ADR (BDRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28.37).
What is the Short Interest ratio of BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?
The outstanding short interest for BIODEXA PHARMACEUTICALS-ADR (BDRX) is 2.22% of its float. Check the ownership tab for more information on the BDRX short interest.
BDRX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to BDRX. When comparing the yearly performance of all stocks, BDRX is a bad performer in the overall market: 97.02% of all stocks are doing better.
BDRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BDRX. The financial health of BDRX is average, but there are quite some concerns on its profitability.
BDRX Financial Highlights
Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -28.37. The EPS increased by 98.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.01% | ||
| ROE | -54.45% | ||
| Debt/Equity | 0 |
BDRX Forecast & Estimates
7 analysts have analysed BDRX and the average price target is 183.6 USD. This implies a price increase of 2620% is expected in the next year compared to the current price of 6.75.